Clinical Trial Update: Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for AMG510 (sotorasib) in patients with unresectable stage III non-small cell lung cancer harboring KRAS G12C mutation; recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KRAZATI (adagrasib)

Snippet

Sponsor: Fundación GECP | Conditions: Non-small Cell Lung Cancer Stage III, KRAS P.G12C | Phase 2 | Status: RECRUITING